RBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $106.00 (from $107.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Form 10-Q Intra-Cellular Therapies For: Jun 30August 7, 2024 7:56 AM Form 8-K Intra-Cellular Therapies For: Aug 02August 7, 2024 7:49 AM Intra-Cellular Therapies (ITCI) Appoints Sanjeev Narula as CFOAugust 7, 2024 7:41 AM Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial OfficerAugust 7, 2024 7:40 AM Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 3c ; Offers GuidanceAugust 7, 2024 7:35 AM Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales GuidanceAugust 7, 2024 7:30 AM